{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:25:21Z","timestamp":1762147521896,"version":"build-2065373602"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Few studies explore the role of definitive radiotherapy for prostate and all metastases in the treatment of low-burden oligometastatic prostate cancer (omPCa). This study aimed to investigate the potential survival benefit of this approach. Moreover, it is the first study to report the outcomes of definitive radiotherapy for local and distant metastatic lesions in patients with omPCa from China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on patients with omPCa who received definitive radiotherapy for the primary site and metastatic lesions between July 2012 and June 2022. The inclusion criteria mandated fewer than 5 oligometastases, excluding regional lymph nodes by imaging examinations with no prior radiotherapy or radical prostatectomy for omPCa. Overall survival (OS) was the primary endpoint, and biochemical progression-free survival (bPFS) and radiological progression-free survival (rPFS) were the secondary endpoint. The Kaplan-Meier method was used to estimate survival rates. Univariate and multivariate analyses were conducted using Cox proportional hazards regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 33 patients, including 31\n                      <jats:italic>de novo<\/jats:italic>\n                      oligometastatic hormone-sensitive prostate cancer (omHSPC) patients and 2 oligometastatic castration-resistant prostate cancer (omCRPC) patients, were enrolled in the study. The median follow-up was 38.8 months (range: 4.2\u201370.6 months). The OS rates of 2-, 3-, and 5-year after treatment were 100.0%, 95.7%,and 81.2%, respectively. Factors correlating with poorer survival were pre-radiotherapy CRPC status, symptomatic lesions, and prior transurethral resection of the prostate (TURP). Multivariate analysis revealed potential associations: concomitant androgen deprivation therapy (ADT) or chemotherapy, non-CRPC status pre-radiotherapy. Lymph node and bone metastases together increased the risk of biochemical recurrence. Acute adverse reactions of Grade 3+ were absent; chronic Grade 3 reactions were 3.0%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Definitive radiotherapy for local\/metastatic lesions demonstrates promising survival with manageable toxicity in omPCa.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1662567","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:21:43Z","timestamp":1762147303000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Definitive radiotherapy for local and metastatic lesions in prostate cancer patients with oligometastases"],"prefix":"10.3389","volume":"15","author":[{"given":"Bichun","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianzhi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiyin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusheng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaojiao","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangyang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215927","article-title":"Prostate cancer treatment: China\u2019s perspective","volume":"550","author":"Liu","year":"2022","journal-title":"Cancer Lett"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31860","article-title":"Oligometast-atic prostate cancer: Reality or figment of imagination","volume":"125","author":"Foster","year":"2019","journal-title":"Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.008","article-title":"Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomized clinical trial: data from the HORRAD trial","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e1003998","DOI":"10.1371\/journal.pmed.1003998","article-title":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: long-term results from the STAMPEDE randomised controlled trial","volume":"19","author":"Parker","year":"2022","journal-title":"PloS Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00d72 factorial design","volume":"404","author":"Bossi","year":"2024","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer: report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2006.05.012","article-title":"Guidelines for primary radiotherapy of patients with prostate cancer","volume":"79","author":"Boehmer","year":"2006","journal-title":"Radiother Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing and castration-resistant prostate cancer","volume":"65","author":"Mottet","year":"2014","journal-title":"Eur Urol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0147191","DOI":"10.1371\/journal.pone.0147191","article-title":"Does radiotherapy for the primary tumor benefit prostate cancer patients with distant metastasis at initial diagnosis","volume":"11","author":"Cho","year":"2016","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.prnil.2020.12.003","article-title":"Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer","volume":"9","author":"Preisser","year":"2021","journal-title":"Prostate Int"},{"key":"B24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.euo.2022.10.002","article-title":"Role of local and\/or metastasis-directed therapy in patients with hormone-sensitive M1a prostate cancer\u2014a systematic review","volume":"6","author":"De Barros","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.7857","article-title":"Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial","volume":"7","author":"Ali","year":"2021","journal-title":"JAMA Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"17471","DOI":"10.1038\/s41598-020-74562-3","article-title":"Local and metastatic curative radiotherapy in patients with de novo oligometastatic prostate cancer","volume":"10","author":"Reverberi","year":"2020","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2020.06.018","article-title":"Clinical outcomes of combined prostate- and metastasis-directed RT in de novo oligometastatic prostate cancer","volume":"5","author":"Imber","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14567","article-title":"Long-term outcomes of EBRT for oligometastatic prostate cancer","volume":"28","author":"Aizawa","year":"2021","journal-title":"Int J Urol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rraa056","article-title":"Treatment results of radiotherapy to both the prostate and metastatic sites in patients with bone metastatic prostate cancer","volume":"62","author":"Inaba","year":"2021","journal-title":"J Radiat Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.02.008","article-title":"Systemic and tumor-directed therapy for oligometastatic prostate cancer: the SOLAR phase 2 trial in de novo oligometastatic prostate cancer","volume":"86","author":"Nickols","year":"2024","journal-title":"Eur Urol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20190353","article-title":"Prostate cancer with low burden skeletal disease at diagnosis: outcome of concomitant radiotherapy on primary tumor and metastases","volume":"93","author":"Deantoni","year":"2020","journal-title":"Br J Radiol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23757","article-title":"Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: A retrospective cohort study","volume":"79","author":"Tsumura","year":"2019","journal-title":"Prostate"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30058","article-title":"Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT)","volume":"122","author":"Wong","year":"2016","journal-title":"Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1662567\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:21:44Z","timestamp":1762147304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1662567\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":34,"alternative-id":["10.3389\/fonc.2025.1662567"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1662567","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"article-number":"1662567"}}